Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) ...

New TREMFYA® (guselkumab) 3-year as-observed data show clinical remission rates of up to 94% (172/183 patients) and endoscopic remission rates of up to 52% (89/172 patients) in adults with moderate to ...

Memory chip shortage drives DRAM and NAND prices up 130% in 2026. Gartner, IDC, and Bernstein data show GPU, CPU, and PC ...

The scramble to power AI data centers with reactors now has a Moscow angle, which puts sanctions and export-control risk squarely into nuclear infrastructure deals.

Most studies of how clouds are responding to climate change focus on clouds over the oceans, rather than over mountains.

UniConverter 18 expands its image and video enhancement capabilities, helping users improve visual quality with less manual ...

New research presented at ENGAGE26 explores how AI tools, ABI testing, pressure mapping, and advanced wound treatments can ...

Persistent Systems (NSE:PERSISTENT) presented its Q2 FY27 investor slides on October 15, 2026, highlighting another quarter ...

Nordex Electrolyzers unveiled the NX2500, a 2.5 MW pressurized alkaline electrolyzer fully designed and tested in Navarra, ...

USA Compression Partners, LP (TXSE: USAC) (“USA Compression”) today announced a cash distribution of $0.525 per common unit ($2.10 on an annualized basis) for the third quarter of 2026. The ...